
|Videos|March 25, 2016
Dr. Julia White on Determining Risk in Patients With Breast Cancer
Author(s)Julia White, MD
Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses the pros and cons of multi-gene assays when trying to determine the risk of local recurrence in patients with breast cancer.
Advertisement
Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses the pros and cons of multi-gene assays when trying to determine the risk of local recurrence in patients with breast cancer. White says in most cases, these assays have already been performed by this point in the treatment sequencing due to oncologists determining if chemotherapy would be the right choice for their hormone-sensitive patients.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































